併用療法のための患者の選択 - Sindax Pharmaceuticals, Inc.

Title:

併用療法のための患者の選択

Document Type and Number:

Japanese Patent JP7206352

Kind Code:

B2

Abstract:

Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.

Inventors:

Peter Oldentrich

Application Number:

JP2021173852A

Publication Date:

January 17, 2023

Filing Date:

October 25, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Sindax Pharmaceuticals, Inc.

International Classes:

G01N33/48; A61K31/4406; A61K31/566; A61K39/395; A61K45/00; A61P11/00; A61P15/14; A61P17/00; A61P35/00; A61P35/02; A61P35/04; A61P43/00; G01N33/483; G01N33/53

Foreign References:

WO2016154068A1
WO2013033656A1
WO2014085461A1
WO2016010879A1

Other References:

KiBem Kim, et al.,Eradication of metastatic mouse cancers resistant to immune checkpoint blockaged by suppression of myeloid-derived cells,Proceeding of the National Academy of Sciences of the United States of America,vol.111, no.32,2014年,pp.11774-11779
Eleni-Kyriaki Vetsika, et al,A circulating subpopulatin of monocitic myeloid-derived suppressor cells as an independent prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients,Journal of Immunology Research,2014年,vol.2014, article ID 659294,pp.1-12

Attorney, Agent or Firm:

Shusaku Yamamoto
Morishita Natsuki
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto

Previous Patent: Contact array optimization for ESD devices

Next Patent: CONTROL DEVICE FOR MAN CONVEYOR